{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:16:18Z","timestamp":1793042178942,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"am","delay-in-days":293,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HHSN275201300017C"],"award-info":[{"award-number":["HHSN275201300017C"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["5P50HD093540"],"award-info":[{"award-number":["5P50HD093540"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejmech.2025.117504","type":"journal-article","created":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T15:27:23Z","timestamp":1742138843000},"page":"117504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Macrocyclic dihydropyridine analogs as pan-BET BD2-preferred inhibitors"],"prefix":"10.1016","volume":"290","author":[{"given":"Jiewei","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimeng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Solberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakriti","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.K.","family":"Pomerantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon E.","family":"Hawkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Sch\u00f6nbrunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8900-9460","authenticated-orcid":false,"given":"Gunda I.","family":"Georg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117504_bib1","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.febslet.2012.04.045","article-title":"The bromodomain interaction module","volume":"586","author":"Filippakopoulos","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2025.117504_bib2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Filippakopoulos","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117504_bib3","first-page":"313","article-title":"Targeting BET bromodomains in cancer","volume":"6","author":"Trojer","year":"2022","journal-title":"Annu. Rev. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117504_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41392-020-00384-4","article-title":"The BET family in immunity and disease","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.117504_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.cell.2012.06.045","article-title":"Small-molecule inhibition of BRDT for male contraception","volume":"150","author":"Matzuk","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117504_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13855","article-title":"A bromodomain\u2013DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT","volume":"7","author":"Miller","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117504_bib7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-8935-7-14","article-title":"Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching","volume":"7","author":"Philpott","year":"2014","journal-title":"Epigenetics Chromatin"},{"key":"10.1016\/j.ejmech.2025.117504_bib8","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1126\/science.aal2066","article-title":"Click chemistry enables preclinical evaluation of targeted epigenetic therapies","volume":"356","author":"Tyler","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117504_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ddtec.2016.06.004","article-title":"Clinical trials for BET inhibitors run ahead of the science","volume":"19","author":"Andrieu","year":"2016","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejmech.2025.117504_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 Study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors","volume":"4","author":"Piha-Paul","year":"2020","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.ejmech.2025.117504_bib11","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.annonc.2020.03.294","article-title":"Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed\/refractory non-Hodgkin's lymphoma","volume":"31","author":"Moreno","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.117504_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1126\/science.aaz8455","article-title":"Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation","volume":"368","author":"Gilan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117504_bib13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","article-title":"Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer","volume":"578","author":"Faivre","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117504_bib14","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/anie.202008625","article-title":"Selective N-terminal BET bromodomain inhibitors by targeting non-conserved residues and structured water displacement","volume":"60","author":"Cui","year":"2021","journal-title":"Angew. Chem."},{"key":"10.1016\/j.ejmech.2025.117504_bib15","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2122506119","article-title":"Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections","volume":"119","author":"Modukuri","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2025.117504_bib16","doi-asserted-by":"crossref","first-page":"9070","DOI":"10.1021\/acs.jmedchem.0c00605","article-title":"Design and synthesis of a highly selective and in vivo-capable inhibitor of the second bromodomain of the bromodomain and extra terminal domain family of proteins","volume":"63","author":"Preston","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117504_bib17","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1021\/acs.jmedchem.3c02104","article-title":"Discovery of novel phenoxyaryl pyridones as bromodomain and extra-terminal domain (BET) inhibitors with high selectivity for the second bromodomain (BD2) to potentially treat acute myeloid leukemia","volume":"67","author":"Jiang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117504_bib18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021102118","article-title":"Discovery and characterization of bromodomain 2\u2013specific inhibitors of BRDT","volume":"118","author":"Yu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2025.117504_bib19","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1021\/acs.jmedchem.6b01336","article-title":"BET bromodomain inhibitors with one-step synthesis discovered from virtual screen","volume":"60","author":"Ayoub","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117504_bib20","article-title":"Correction to BET bromodomain inhibitors with one-step synthesis discovered from virtual screen","volume":"60","author":"Ayoub","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117504_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200288","article-title":"1,4-Dihydropyridinebutyrolactone-derived ring-opened ester and amide analogs targeting BET bromodomains","volume":"355","author":"Jiang","year":"2022","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejmech.2025.117504_bib22","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1021\/acs.jmedchem.7b00017","article-title":"Fragment-based, structure-enabled discovery of novel pyridones and pyridone macrocycles as potent bromodomain and extra-terminal domain (BET) family bromodomain inhibitors","volume":"60","author":"Wang","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117504_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115023","article-title":"Cyclization strategy leads to highly potent bromodomain and extra-terminal (BET) bromodomain inhibitors for the treatment of acute liver injury","volume":"247","author":"Chen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117504_bib24","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/acsmedchemlett.8b00380","article-title":"Design, synthesis, and characterization of a fluorescence polarization pan-BET bromodomain probe","volume":"9","author":"Paulson","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117504_bib25","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1021\/acs.jmedchem.5b01447","article-title":"Protein-observed fluorine NMR: a bioorthogonal approach for small molecule discovery","volume":"59","author":"Arntson","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117504_bib26","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1021\/acschembio.0c00720","article-title":"Quantifying the selectivity of protein\u2013protein and small molecule interactions with fluorinated tandem bromodomain reader proteins","volume":"15","author":"Kalra","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117504_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202100407","article-title":"Dihydropyridine lactam analogs targeting BET bromodomains","volume":"17","author":"Jiang","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117504_bib28","doi-asserted-by":"crossref","first-page":"10441","DOI":"10.1021\/acs.jmedchem.2c00453","article-title":"Bivalent BET bromodomain inhibitors confer increased potency and selectivity for BRDT via protein conformational plasticity","volume":"65","author":"Guan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117504_bib29","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117504_bib30","doi-asserted-by":"crossref","first-page":"15772","DOI":"10.1021\/acs.jmedchem.1c01096","article-title":"Differential BET bromodomain inhibition by dihydropteridinone and pyrimidodiazepinone kinase inhibitors","volume":"64","author":"Karim","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117504_bib31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ab.2004.05.055","article-title":"Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization","volume":"332","author":"Nikolovska-Coleska","year":"2004","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2025.117504_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"Xds","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2025.117504_bib33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2025.117504_bib34","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2025.117504_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: all-atom structure validation for macromolecular crystallography","volume":"66","author":"Chen","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2025.117504_bib36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1107\/S0021889810015608","article-title":"phenix.model_vs_data: a high-level tool for the calculation of crystallographic model and data statistics","volume":"43","author":"Afonine","year":"2010","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2025.117504_bib37","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1021\/jm500734a","article-title":"Importance of purity evaluation and the potential of quantitative (1)H NMR as a purity assay","volume":"57","author":"Pauli","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117504_bib38","doi-asserted-by":"crossref","first-page":"9061","DOI":"10.1021\/acs.jmedchem.5b01667","article-title":"Correction to importance of purity evaluation and the potential of quantitative (1)H NMR as a purity assay","volume":"58","author":"Pauli","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117504_bib39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/mrc.5099","article-title":"Quantitative NMR (qNMR) for pharmaceutical analysis: the pioneering work of George Hanna at the US FDA","volume":"59","author":"Jaki","year":"2021","journal-title":"Magn. Reson. Chem."},{"key":"10.1016\/j.ejmech.2025.117504_bib40","doi-asserted-by":"crossref","first-page":"12162","DOI":"10.1021\/acs.analchem.1c02056","article-title":"The qNMR summit 5.0: proceedings and status of qNMR technology","volume":"93","author":"Giancaspro","year":"2021","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejmech.2025.117504_bib41","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cmdc.200900468","article-title":"Improved model of lanosterol 14alpha-demethylase by ligand-supported homology modeling: validation by virtual screening and azole optimization","volume":"5","author":"Sheng","year":"2010","journal-title":"ChemMedChem"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425002697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425002697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:22:34Z","timestamp":1745454154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425002697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":41,"alternative-id":["S0223523425002697"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117504","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macrocyclic dihydropyridine analogs as pan-BET BD2-preferred inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117504"}}